An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients.
about
An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh
2018年學術文章
@zh-hant
name
An open-label, multiple ascend ...... mumab in viremic HIV patients.
@en
An open-label, multiple ascend ...... mumab in viremic HIV patients.
@nl
type
label
An open-label, multiple ascend ...... mumab in viremic HIV patients.
@en
An open-label, multiple ascend ...... mumab in viremic HIV patients.
@nl
prefLabel
An open-label, multiple ascend ...... mumab in viremic HIV patients.
@en
An open-label, multiple ascend ...... mumab in viremic HIV patients.
@nl
P2093
P2860
P1433
P1476
An open-label, multiple ascend ...... mumab in viremic HIV patients.
@en
P2093
Alan J Korman
Blisse Vakkalagadda
David Gardiner
Dennis Grasela
Elizabeth Colston
Israel Lowy
R Pat Bucy
P2860
P304
P356
10.1371/JOURNAL.PONE.0198158
P407
P577
2018-06-07T00:00:00Z